Evidence map›Paper›PMID 26848150›Full record

ReviewEuropean heart journal2017

Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2.

Hans-Christoph Diener, James Aisenberg, Jack Ansell, Dan Atar, Günter Breithardt, John Eikelboom, Michael D Ezekowitz, Christopher B Granger, Jonathan L Halperin, Stefan H Hohnloser and 6 more

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in European heart journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 6 pooled it
19.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 6 syntheses or guidelines pooled it, 141 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Guideline
  6. [Guidelines from the DOG, RG and BVA: retinal artery occlusion : November 2016 status].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2017
    Guideline
  7. Trial
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Observational
  18. Review
  19. Optimizing adherence and persistence to non-vitamin K antagonist oral anticoagulant therapy in atrial fibrillation.European heart journal supplements : journal of the European Society of Cardiology · 2022
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 13 institutions in 6 countries.

Hans-Christoph DienerDepartment of Neurology, University Hospital Essen, Essen, Germany.
James AisenbergIcahn School of Medicine at Mount Sinai, New York, USA.
Jack AnsellHofstra North Shore/LIJ School of Medicine, Hempstead, USA.
Dan AtarDivision of Medicine, Oslo University Hospital, Ullevål and University of Oslo, Norway.
Günter BreithardtDivision of Rhythmology, Department of Cardiovascular Medicine, Hospital of the University Münster, Münster, Germany.
John EikelboomPopulation Health Research Institute, McMaster University, Hamilton, ON, Canada.
Michael D EzekowitzCardiovascular Research Foundation, New York, NY, USA.
Christopher B GrangerDepartment of Medicine, Duke University, Durham, NC, USA.
Jonathan L HalperinIcahn School of Medicine at Mount Sinai, Mount Sinai Medical Center, New York, NY, USA.
Stefan H HohnloserDivision of Clinical Electrophysiology, Department of Cardiology, J. W. Goethe University, Frankfurt, Germany.
Elaine M HylekBoston Medical Center, Boston University School of Medicine, Boston, MA, USA.
Paulus KirchhofInstitute of Cardiovascular Sciences, University of Birmingham, SWBH and UHB NHS Trusts, Birmingham, UK.
Deirdre A LaneUniversity of Birmingham, Institute of Cardiovascular Sciences, City Hospital, Birmingham, UK.
Freek W A VerheugtAfdeling Cardiologie, Hartcentrum OLVG, Amsterdam, The Netherlands.
Roland VeltkampImperial College London, London, UK.
Gregory Y H LipUniversity of Birmingham, Birmingham, UK.
Icahn School of Medicine at Mount Sinai · USUniversity of Birmingham · GBBoston University · USDuke University · USEssen University Hospital · DEGoethe University Frankfurt · DEHofstra University · USImperial College London · GBLankenau Medical Center · USOslo University Hospital · NOPopulation Health Research Institute · CAUniversity Hospital Münster · DEUniversity of Münster · DE

Funding

British Heart Foundation FS/13/43/30324
6 · The paper itself

Abstract

The choice of oral anticoagulant (OAC) for patients with atrial fibrillation (AF) may be influenced by individual clinical features or by patterns of risk factors and comorbidities. We reviewed analyses of subgroups of patients from trials of vitamin K antagonists vs. non-vitamin K oral anticoagulants (NOACs) for stroke prevention in AF with the aim to identify patient groups who might benefit from a particular OAC more than from another. In addition, we discuss the timing of initiation of anticoagulation. In the second of a two-part review, we discuss the use of NOAC for stroke prevention in the following subgroups of patients with AF: (vii) secondary stroke prevention in patients after stroke or transient ischaemic attack (TIA), (viii) patients with acute stroke requiring thrombolysis or thrombectomy, (ix) those initiating or restarting OAC treatment after stroke or TIA, (x) those with renal impairment on dialysis, (xi) the elderly, (xii) those at high risk of gastrointestinal bleeding, and (xiii) those with hypertension. In addition, we discuss adherence and compliance. Finally, we present a summary of treatment suggestions. In specific subgroups of patients with AF, evidence supports the use of particular NOACs and/or particular doses of anticoagulant. The appropriate choice of treatment for these subgroups will help to promote optimal clinical outcomes.

Indexed as

Administration, OralAgedAged, 80 and overAge FactorsAnticoagulantsAtrial FibrillationClinical Decision-MakingContraindications, DrugDrug Administration ScheduleGastrointestinal HemorrhageHumansHypertensionIschemic Attack, TransientMedication AdherenceRenal DialysisRenal Insufficiency, ChronicAnticoagulantsAnticoagulationNon-valvular atrial fibrillationNon-vitamin K oral antagonistStroke prevention

Identifiers

PMID26848150
PMCPMC5837363
OpenAlexW2915181639

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.